Niraparib (Standard)

CAT: 0804-HY-10619R-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10619R-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Niraparib (Standard) is the analytical standard of Niraparib. This product is intended for research and analytical applications. Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity[1][2][3].
CAS Number
[1038915-60-4]
Product Name Alternative
MK-4827 (Standard)
UNSPSC
12352005
Target
Apoptosis; PARP; Reference Standards
Type
Reference Standards
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Others
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/niraparib-standard.html
Smiles
NC(C1=CC=CC2=CN(C3=CC=C([C@H]4CNCCC4)C=C3)N=C21)=O
Molecular Formula
C19H20N4O
Molecular Weight
320.39
References & Citations
[1]Jones P, et al. Discovery of 2-{4-[ (3S) -piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827) : a novel oral poly (ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52 (22) :7170-85.|[2]Bridges KA, et al. Niraparib (MK-4827), a novel poly (ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5 (13) :5076-86.|[3]Wang L, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30 (6) :2113-20.|[4]Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375 (22) :2154-2164.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Popular Products